GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascelia Pharma AB (FRA:7ZA) » Definitions » Stock Based Compensation

Ascelia Pharma AB (FRA:7ZA) Stock Based Compensation : €-0.01 Mil (TTM As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Ascelia Pharma AB Stock Based Compensation?

Ascelia Pharma AB's Stock Based Compensation for the three months ended in Mar. 2025 was €0.05 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 was €-0.01 Mil.


Ascelia Pharma AB Stock Based Compensation Historical Data

The historical data trend for Ascelia Pharma AB's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascelia Pharma AB Stock Based Compensation Chart

Ascelia Pharma AB Annual Data
Trend Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24
Stock Based Compensation
Get a 7-Day Free Trial 0.77 0.58 0.15 0.26 0.38

Ascelia Pharma AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 -0.14 0.07 - 0.05

Ascelia Pharma AB Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.01 Mil.


Ascelia Pharma AB Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Ascelia Pharma AB's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascelia Pharma AB Business Description

Traded in Other Exchanges
Address
Hyllie Boulevard 34, Malmo, SWE, SE-215 32
Ascelia Pharma AB is an oncology-dedicated drug development company located in Malmo Sweden focused on orphan oncology It develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway The company has two drug candidates Orviglance and Oncoral in clinical development.

Ascelia Pharma AB Headlines

No Headlines